Rachel Saunders-Pullman

Rachel Saunders-Pullman

Auto-generated profile, based on publicly available information

Rachel Saunders-Pullman

Department of Neurology, Icahn School of Medicine at Mount Sinai and Mount Sinai Beth Israel, 521 W 57th St. Flr 6, New York, NY, 10019, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin
RARoger Albin
Roger Albin
RARoy Alcalay
Roy Alcalay
DBDebra Babcock
Debra Babcock
VBVikram Bajaj
Vikram Bajaj
JZJing Zhang
Jing Zhang
The recent advent of an “ecosystem” of shared biosample biorepositories and data sets will aid efforts to define biomarkers for Parkinson’s disease.

1 April 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RORoberto A. Ortega
Roberto A. Ortega
CWCuiling Wang
Cuiling Wang
DRDeborah Raymond
Deborah Raymond
NBNicole Bryant
Nicole Bryant
CSClemens R. Scherzer
Clemens R. Scherzer
RSRachel Saunders-Pullman
Rachel Saunders-Pullman
Variants in the leucine-rich repeat kinase 2 (LRRK2; OMIM 609007) and glucocerebrosidase (GBA; OMIM 606463) genes are frequent and worldwide genetic contributors to Parkinson disease (PD) susceptibility.1,2 LRRK2 variations occur in approximately 2% of PD overall, and up to 40% of PD in certain ethnic groups, particularly individuals of Ashkenazi Jewish or Arabian Berber descent.1 GBA variation and risk variants in GBA may be present in as many of 10% of PD worldwide and in approximately 15% or greater in PD among individuals of Ashkenazi Jewish descent.2-4 Wide ranges in conferred disease risk exist based on allelic heterogeneity. The penetrance of LRRK2 variations (specifically G2019S), or the chance that a carrier of this variation will manifest PD by late adulthood, has been estimated at 26% to 43% and is lower in individuals with GBA variations, ranging from 9% to 19%.5-8 Therefore, additional risk factors are clearly at play.9-11 One potential critical interaction is the association of GBA and LRRK2 variations in carriers of both variations (hereafter, LRRKR2/GBA).

27 June 2023 in Movement Disorders
Verified
Journal Article
Open access
GPGian Pal
Gian Pal
LCLola Cook
Lola Cook
JSJeanine Schulze
Jeanine Schulze
JVJennifer Verbrugge
Jennifer Verbrugge
RARoy N. Alcalay
Roy N. Alcalay
CKChristine Klein
Christine Klein
Genetic testing for persons with Parkinson's disease is becoming increasingly common. Significant gains have been made regarding genetic testing methods, and testing is becoming more readily available in clinical, research, and direct‐to‐consumer settings. Although the potential utility of clinical testing is expanding, there are currently no proven gene‐targeted therapies, but clinical trials are underway. Furthermore, genetic testing practices vary widely, as do knowledge and attitudes of relevant stakeholders. The specter of testing mandates financial, ethical, and physician engagement, and there is a need for guidelines to help navigate the myriad of challenges. However, to develop guidelines, gaps and controversies need to be clearly identified and analyzed. To this end, we first reviewed recent literature and subsequently identified gaps and controversies, some of which were partially addressed in the literature, but many of which are not well delineated or researched. Key gaps and controversies include: (1) Is genetic testing appropriate in symptomatic and asymptomatic individuals without medical actionability? (2) How, if at all, should testing vary based on ethnicity? (3) What are the long‐term outcomes of consumer‐ and research‐based genetic testing in presymptomatic PD? (4) What resources are needed for clinical genetic testing, and how is this impacted by models of care and cost‐benefit considerations? Addressing these issues will help facilitate the development of consensus and guidelines regarding the approach and access to genetic testing and counseling. This is also needed to guide a multidisciplinary approach that accounts for cultural, geographic, and socioeconomic factors in developing testing guidelines. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

26 July 2019 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
IAIlir Agalliu
Ilir Agalliu
RORoberto A. Ortega
Roberto A. Ortega
MLMarta San Luciano
Marta San Luciano
AMAnat Mirelman
Anat Mirelman
CPClaustre Pont‐Sunyer
Claustre Pont‐Sunyer
RSRachel Saunders‐Pullman
Rachel Saunders‐Pullman

13 June 2023 in Movement Disorders
Verified
Journal Article
Closed access
RSRachel Saunders‐Pullman
Rachel Saunders‐Pullman
DRDeborah Raymond
Deborah Raymond
RORoberto A. Ortega
Roberto A. Ortega
ASAli Shalash
Ali Shalash
EGEmilia Gatto
Emilia Gatto
TSTatyana Simuni
Tatyana Simuni

3 June 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
RSRachel Saunders-Pullman
Rachel Saunders-Pullman
RORoberto Angel Ortega
Roberto Angel Ortega
CWCuiling Wang
Cuiling Wang
DRDeborah Raymond
Deborah Raymond
SESonya Elango
Sonya Elango
SBSusan B. Bressman
Susan B. Bressman
Background and Objectives There is clinical and phenotypic heterogeneity in LRRK2 G2019S Parkinson disease (PD), including loss of smell. Olfactory scores have defined subgroups of LRRK2 PD at baseline. We now extend this work longitudinally to better determine features associated with olfactory classes and to gain further insight into this heterogeneity. Methods Evaluation of 162 patients with LRRK2 PD and 198 patients with idiopathic PD (IPD) from the LRRK2 Ashkenazi Jewish Consortium was performed, with follow-up available for 92 patients with LRRK2 PD and 74 patients with IPD. Olfaction (University of Pennsylvania Smell Identification Test [UPSIT]), motor function (Unified Parkinson Disease Rating Scale), and cognition (Montreal Cognitive Assessment), as well as sleep, nonmotor, and mood, were measured. Gaussian mixture models were applied on the UPSIT percentile score to determine subgroups based on olfactory performance. Linear mixed effects models, using PD duration as the time scale, assessed the relationship between UPSIT subgroup membership and motor/cognitive change. Results Baseline olfaction was better in LRRK2 PD compared with IPD (mean UPSIT ± SD: 24.2 ± 8.8 vs 18.9 ± 7.6), with higher mean percentile scores (difference: 15.3 ± 11.6) (p < 0.001) and less frequent hyposmia (55.6% vs 85.4%; p < 0.001). Analysis suggested 3 classes among LRRK2 PD. Age at onset in LRRK2 PD was earlier in the worst olfaction group (group 1), compared with groups 2 and 3 (54.5 ± 11.1 vs 61.7 ± 9.3) (p = 0.012), and separately in the hyposmic group overall (55.0 ± 11.3 vs 61.7 ± 9.1) (p < 0.001). Longitudinal motor deterioration in LRRK2 PD was also significantly faster in the worst UPSIT group than the best UPSIT group (group 3 vs group 1: B = 0.31, SE = 0.35 vs B = 0.96, SE = 0.28) (rate difference = −0.65, SE = 0.29) (p = 0.03). However, olfactory group membership was not significantly associated with cognitive decline. Discussion In this large LRRK2 cohort with longitudinal analysis, we extend prior work demonstrating subgroups defined by olfaction in LRRK2 G2019S PD and show that the worst olfaction group has earlier age at PD onset and more rapid motor decline. This supports a subgroup of LRRK2 PD that might show more rapid change in a clinical trial of LRRK2-related agents and highlights the need to integrate careful phenotyping into allocation schema in clinical trials of LRRK2-related agents. Classification of Evidence This study provides Class II evidence that worse olfactory scores were associated with an earlier age at symptomatic onset and a faster rate of motor deterioration in patients with LRRK2 PD.